Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

W M van Weerden; C Bangma; R de Wit

doi:10.1038/sj.bjc.6604822

Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

Br J Cancer. 2009 Jan 13;100(1):13-8. doi: 10.1038/sj.bjc.6604822. Epub 2008 Dec 16.

Authors

W M van Weerden¹, C Bangma, R de Wit

Affiliation

¹ Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands. w.vanweerden@erasmusmc.nl

Abstract

With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

Publication types

Review

MeSH terms

Androgen Antagonists / therapeutic use
Animals
Cell Line, Tumor
Clinical Trials, Phase II as Topic
Docetaxel
Humans
Male
Prostate-Specific Antigen / blood
Prostatic Neoplasms / drug therapy*
Taxoids / therapeutic use
Xenograft Model Antitumor Assays / methods*

Substances

Androgen Antagonists
Taxoids
Docetaxel
Prostate-Specific Antigen